

HR 4278

To direct the Comptroller General of the United States to conduct a study on how direct-to-consumer pharmaceutical advertising negatively impacts drug costs to consumers, and for other purposes.

Congress: 117 (2021–2023, Ended)

Chamber: House

Policy Area: Health

Introduced: Jun 30, 2021

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Jul 1, 2021)

Official Text: <https://www.congress.gov/bill/117th-congress/house-bill/4278>

Sponsor

Name: Rep. Murphy, Gregory [R-NC-3]

Party: Republican • **State:** NC • **Chamber:** House

Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Harshbarger, Diana [R-TN-1]	R · TN		Jun 30, 2021

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Jul 1, 2021

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Summary (as of Jun 30, 2021)

This bill requires the Government Accountability Office to study and report on how direct-to-consumer pharmaceutical advertising negatively impacts drug costs to consumers.

Actions Timeline

- **Jul 1, 2021:** Referred to the Subcommittee on Health.
- **Jun 30, 2021:** Introduced in House
- **Jun 30, 2021:** Referred to the House Committee on Energy and Commerce.